Caliper Life Sciences to Acquire Cambridge Research & Instrumentation for $20M

Caliper Life Sciences, Inc. CALP today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis systems will expand Caliper's life sciences tools portfolio, particularly as it bridges into clinical research, pathology and clinical market applications. Under the agreement, in exchange for all of CRi's outstanding equity securities, Caliper will issue common stock valued at approximately $10.5 million, pay cash of approximately $7.5 million, and assume CRi indebtedness of approximately $2.0 million.